Blood-based biomarkers for Alzheimer's disease
Leuzy, Antoine LU ; Mattsson-Carlgren, Niklas LU
; Palmqvist, Sebastian
LU
; Janelidze, Shorena
LU
; Dage, Jeffrey L.
and Hansson, Oskar
LU
(2022)
In EMBO Molecular Medicine
14(1).
- Abstract
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be... (More)
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.
(Less)
- author
- Leuzy, Antoine
LU
; Mattsson-Carlgren, Niklas
LU
; Palmqvist, Sebastian
LU
; Janelidze, Shorena
LU
; Dage, Jeffrey L.
and Hansson, Oskar
LU
- organization
- publishing date
- 2022-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- EMBO Molecular Medicine
- volume
- 14
- issue
- 1
- article number
- e14408
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:34859598
- scopus:85120437804
- ISSN
- 1757-4676
- DOI
- 10.15252/emmm.202114408
- language
- English
- LU publication?
- yes
- id
- 0b31b926-dd0f-443a-981d-b69fd618bb6d
- date added to LUP
- 2022-01-17 14:05:04
- date last changed
- 2025-03-11 05:28:43
@article{0b31b926-dd0f-443a-981d-b69fd618bb6d,
abstract = {{<p>Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.</p>}},
author = {{Leuzy, Antoine and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Janelidze, Shorena and Dage, Jeffrey L. and Hansson, Oskar}},
issn = {{1757-4676}},
language = {{eng}},
number = {{1}},
publisher = {{Wiley-Blackwell}},
series = {{EMBO Molecular Medicine}},
title = {{Blood-based biomarkers for Alzheimer's disease}},
url = {{http://dx.doi.org/10.15252/emmm.202114408}},
doi = {{10.15252/emmm.202114408}},
volume = {{14}},
year = {{2022}},
}